Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia

Background Intimal hyperplasia remains the primary cause of vein graft failure for the 1 million yearly bypass procedures performed using human saphenous vein (HSV) grafts. This response to injury is caused in part by the harvest and preparation of the conduit. The use of Brilliant Blue FCF (FCF) re...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of vascular surgery 2016-08, Vol.64 (2), p.471-478
Hauptverfasser:	Osgood, Michael J., MD, Sexton, Kevin, MD, Voskresensky, Igor, MD, Hocking, Kyle, PhD, Song, Jun, BA, Komalavilas, Padmini, PhD, Brophy, Colleen, MD, Cheung-Flynn, Joyce, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Benzenesulfonates - pharmacology Cell Line Cell Movement - drug effects Cell Proliferation - drug effects Coloring Agents - pharmacology Humans Hyperplasia Jugular Veins - drug effects Jugular Veins - metabolism Jugular Veins - pathology Jugular Veins - transplantation Models, Animal Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - metabolism Muscle, Smooth, Vascular - pathology Myocytes, Smooth Muscle - drug effects Myocytes, Smooth Muscle - metabolism Myocytes, Smooth Muscle - pathology Neointima Organ Culture Techniques Purinergic P2X Receptor Antagonists - pharmacology Rabbits Rats Receptors, Purinergic P2X7 - drug effects Receptors, Purinergic P2X7 - metabolism Saphenous Vein - drug effects Saphenous Vein - metabolism Saphenous Vein - pathology Saphenous Vein - transplantation Signal Transduction - drug effects Surgery Time Factors Tissue and Organ Harvesting - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!